# Phase 2 Lymphoma, B-Cell trials recruiting: 33 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 33 trials in phase 2 for Lymphoma, B-Cell that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Lymphoma, B-Cell trials: 33 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/lymphoma-b-cell

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 33
- Recruiting or not yet: 33
- Read on: November 19, 2026

## Trials

The 25 newest of 33, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 5, 2026 | NCT07917832 | Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large... | M.D. Anderson Cancer Center | Phase 2 | Not yet recruiting | Multi Center, Phase 2, Golcadomide, Glofitamab, Polauzumab, Vedotin, G2p, B Cell Lymphoma | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917832) |
| October 20, 2026 | NCT07883135 | Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell Lymphomas | National Research Center for Hematology, Russia | Phase 2 | Recruiting | Aggressive B-cell Non-Hodgkin Lymphoma (aNHL), Relapsed or Refractory B-cell Lymphoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883135) |
| August 18, 2026 | NCT07771361 | BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma | Luminary Therapeutics | Phase 2 | Not yet recruiting | Non-Hodgkin Lymphoma Refractory/ Relapsed, Multiple Myeloma Refractory, Multiple Myeloma in Relapse, Non-Hodgkin... | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07771361) |
| July 17, 2026 | NCT07711483 | GLORY: Glofit-GemOx With Liso-Cel For Lymphoma | Massachusetts General Hospital | Phase 2 | Recruiting | Lymphoma, B-cell Lymphomas, Relapsed/Refractory Large B-cell Lymphoma, Large B-cell Lymphoma | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07711483) |
| June 3, 2026 | NCT07622784 | Pirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell Lymphoma | Sun Yat-sen University | Phase 2 | Not yet recruiting | Relapsed or Refractory B-cell Lymphoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07622784) |
| May 18, 2026 | NCT07593482 | Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a... | Swiss Cancer Institute | Phase 2 | Recruiting | B-cell Lymphoma | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07593482) |
| May 15, 2026 | NCT07588698 | Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Non-Hodgkin's B-cell Lymphoma, Lymphoma Non-Hodgkin, Diffuse Large B-Cell Lymphoma (DLBCL) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07588698) |
| May 6, 2026 | NCT07569965 | Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL | Miltenyi Biomedicine GmbH | Phase 2 | Not yet recruiting | Mantle Cell Lymphoma (MCL) | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07569965) |
| March 31, 2026 | NCT07502872 | TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma | Brown University | Phase 2 | Not yet recruiting | Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Lymphoma, Lymphoma, B-Cell | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07502872) |
| March 17, 2026 | NCT07477366 | Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma | ImmunityBio, Inc. | Phase 2 | Not yet recruiting | Relapsed B-Cell Non-Hodgkin Lymphoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07477366) |
| August 15, 2025 | NCT07125872 | Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma | ImmunityBio, Inc. | Phase 2 | Recruiting | Relapsed B-Cell Non Hodgkin Lymphoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07125872) |
| July 31, 2025 | NCT07097363 | Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment... | University of Washington | Phase 2 | Recruiting | B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07097363) |
| July 22, 2025 | NCT07077512 | Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma | Sun Yat-sen University | Phase 2 | Recruiting | Large B Cell Diffuse Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07077512) |
| May 2, 2025 | NCT06954805 | Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD) | Sponsor not shown (see the record) | Phase 2 | Recruiting | Lymphoma, Lymphoma, B-Cell | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06954805) |
| December 9, 2024 | NCT06723457 | Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma | Sponsor not shown (see the record) | Phase 2 | Recruiting | Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory... | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06723457) |
| November 21, 2024 | NCT06698484 | To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma... | National University of Malaysia | Phase 2 | Recruiting | Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06698484) |
| October 17, 2024 | NCT06646666 | ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT | Ruijin Hospital | Phase 2 | Not yet recruiting | B-cell Non Hodgkin Lymphoma | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06646666) |
| August 22, 2024 | NCT06566586 | A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell... | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 | Recruiting | B-cell Lymphoma | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06566586) |
| August 2, 2024 | NCT06534762 | Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study | Zhejiang Provincial People's Hospital | Phase 2 | Recruiting | NSCLC, SCLC, Colorectal Cancer, Pancreas Cancer, TNBC - Triple-Negative Breast Cancer, DLBCL - Diffuse Large B Cell... | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06534762) |
| July 30, 2024 | NCT06526793 | Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL | AstraZeneca | Phase 2 | Recruiting | B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL) | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06526793) |
| July 18, 2024 | NCT06508931 | Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms | Miltenyi Biomedicine GmbH | Phase 2 | Recruiting | B-Cell Neoplasm | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06508931) |
| June 17, 2024 | NCT06462248 | Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies | Sponsor not shown (see the record) | Phase 2 | Recruiting | Lymphoma, Nonhodgkin, Leukemia, Lymphocytic | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06462248) |
| April 15, 2024 | NCT06365671 | CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors | Ruijin Hospital | Phase 2 | Recruiting | B-cell Non Hodgkin Lymphoma | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06365671) |
| April 5, 2024 | NCT06350318 | Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | Recruiting | Follicular Lymphoma, Marginal Zone Lymphoma, B-Cell Lymphoma | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06350318) |
| January 19, 2024 | NCT06213311 | A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma | M.D. Anderson Cancer Center | Phase 2 | Recruiting | B Cell Lymphoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06213311) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Miltenyi Biomedicine GmbH](https://specstream.ai/data/clinical-trials/company/miltenyi-biomedicine-gmbh) | 3 |
| Ruijin Hospital | 3 |
| M.D. Anderson Cancer Center | 3 |
| [ImmunityBio, Inc.](https://specstream.ai/data/clinical-trials/company/immunitybio-inc) | 2 |
| Sun Yat-sen University | 2 |
| Brown University | 2 |
| University of Washington | 1 |
| H. Lee Moffitt Cancer Center and Research Institute | 1 |
| The First Affiliated Hospital of Xiamen University | 1 |
| Zhejiang Provincial People's Hospital | 1 |
| Swiss Cancer Institute | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| Massachusetts General Hospital | 1 |
| City of Hope Medical Center | 1 |
| National Research Center for Hematology, Russia | 1 |
| Beijing Tongren Hospital | 1 |
| National University of Malaysia | 1 |
| [Chia Tai Tianqing Pharmaceutical Group Co., Ltd.](https://specstream.ai/data/clinical-trials/company/chia-tai-tianqing-pharmaceutical-group-co-ltd) | 1 |
| Luminary Therapeutics | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 15 |
| China | 11 |
| Canada | 2 |
| France | 2 |
| Germany | 2 |
| Italy | 2 |
| Switzerland | 1 |
| Australia | 1 |
| Brazil | 1 |
| Denmark | 1 |
| Hong Kong | 1 |
| Japan | 1 |
| South Korea | 1 |
| Spain | 1 |
| Sweden | 1 |
| Taiwan | 1 |
| United Kingdom | 1 |
| Netherlands | 1 |
| Russia | 1 |
| Malaysia | 1 |
| South Africa | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Packaging companies in the United States](https://specstream.ai/data/businesses/packaging-companies/united-states)
- [Hepatology practices in the United States](https://specstream.ai/data/businesses/hepatology-practices/united-states)
- [Computer hardware companies in the United States](https://specstream.ai/data/businesses/computer-hardware-companies/united-states)
- [Agricultural services in the United States](https://specstream.ai/data/businesses/agricultural-services/united-states)
- [Rheumatology practices in the United States](https://specstream.ai/data/businesses/rheumatology-practices/united-states)
- [Malaysian restaurants in the United States](https://specstream.ai/data/businesses/malaysian-restaurants/united-states)
